Trevena (NASDAQ:TRVN) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN) in a report issued on Thursday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Trevena Stock Down 9.2%

Shares of NASDAQ:TRVN opened at $1.09 on Thursday. The company’s fifty day moving average is $1.23 and its two-hundred day moving average is $1.53. Trevena has a 12-month low of $0.95 and a 12-month high of $10.99. The company has a market cap of $941,760.00, a P/E ratio of -0.02 and a beta of 0.87.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.